Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 8, 2026

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as long as 1.5 years

GlobeNewsWire • Jun 3, 2026

Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?

Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.

Zacks Investment Research • May 20, 2026

Cabaletta Bio (CABA) Upgraded to Buy: Here's Why

Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • May 18, 2026

Cabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In Autoimmune

Cabaletta Bio, Inc. is reaffirmed as a Buy despite recent share price volatility, driven by tangible clinical and manufacturing progress. Key catalysts include registrational trials for rese-cel in myositis, promising early data in myasthenia gravis and pemphigus vulgaris, and upcoming SLE and SSc readouts. Rese-cel's outpatient-friendly safety profile, removal of preconditioning, and scalable manufacturing platform position CABA for significant autoimmune market opportunities.

Seeking Alpha • May 14, 2026

Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV ® study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares' industrialized, automated manufacturing

GlobeNewsWire • May 14, 2026

Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting

A single infusion of the lowest dose of rese-cel administered without preconditioning, after discontinuation of all immunomodulators, demonstrated compelling drug-free responses for 6 months in 2 of 4 refractory patients; next dose cohort actively enrolling Translational data from the first two patients dosed with rese-cel manufactured on the automated Cell Shuttle™ platform showed pharmacokinetic and pharmacodynamic data consistent with other patients dosed in the RESET™ clinical program ASGCT 2026 presentations reinforce Cabaletta's focus on optimizing the patient and physician experience through simplified treatment regimens and scalable reliable manufacturing PHILADELPHIA, May 14, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell therapies designed specifically for patients with autoimmune diseases, today announced new clinical and translational data from the first four patients in the lowest dose cohort in RESET-PV® evaluating preconditioning-free (PC-free) rese-cel (resecabtagene autoleucel) and initial manufacturing and translational data from the first two autoimmune patients treated with rese-cel manufactured using the automated Cellares Cell Shuttle platform in the RESET clinical development program. These data are being presented in separate poster presentations today at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting in Boston, MA.

GlobeNewsWire • May 14, 2026

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten offering of 51,725,000 shares of common stock. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $150 million. The offering is expected to close on or about May 5, 2026, subject to the satisfaction of customary closing conditions. The financing included participation from Bain Capital Life Sciences, Adage Capital Management, Cormorant Asset Management and other existing investors, multiple new mutual and sovereign wealth funds and Eli Lilly and Company.

GlobeNewsWire • May 4, 2026

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per batch that is among the lowest in the industry  Initial translational data from the first two patients dosed with rese-cel manufactured by Cellares will be presented at the ASGCT conference in May PHILADELPHIA and SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, and Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced a commercial agreement to supply rese-cel (resecabtagene autoleucel) using Cellares' automated Cell Shuttle and through future implementation of Cellares' Cell Q platform.

GlobeNewsWire • Apr 28, 2026

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has entered into a 10-year commercial supply agreement with Cabaletta Bio Inc. (Nasdaq: CABA) for the automated manufacture of rese-cel (resecabtagene autoleucel), Cabaletta's investigational CAR T cell therapy for autoimmune diseases. The agreement secures the long-term manufacturing capacity and supply predictability required to address the global.

Business Wire • Apr 28, 2026